v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting
Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:
Three Months Ended June 30,
20262025
Revenue from collaborative arrangement$— $— 
Less:
Research and development:
     INO-31073,877,243 3,930,320 
     INO-3112 and other Immuno-oncology379,056 450,094 
     Other research and development programs (a)899,547 1,141,153 
     Engineering and device-related2,665,853 5,084,662 
     Stock-based compensation299,295 321,688 
     Other unallocated expenses 2,705,555 3,593,490 
General and administrative7,797,973 8,563,112 
Total operating expenses18,624,522 23,084,519 
Interest income363,847 610,638 
Change in fair value of common stock warrant liabilities13,868,616 (1,878,010)
Gain on investment in affiliated entity— 776,373 
Net unrealized gain on available-for-sale equity securities94,221 759,289 
Other expense, net(1,714,620)(703,183)
Net loss$(6,012,458)$(23,519,412)
Six Months Ended June 30,
20262025
Revenue from collaborative arrangement$— $65,343 
Less:
Research and development:
     INO-31077,882,534 7,437,662 
     INO-3112 and other Immuno-oncology744,284 1,134,543 
     Other research and development programs (a)1,982,830 1,879,213 
     Engineering and device-related6,706,969 10,146,472 
     Stock-based compensation574,233 875,082 
     Other unallocated expenses 7,005,806 9,139,337 
General and administrative15,677,859 17,588,082 
Total operating expenses40,574,515 48,200,391 
Interest income803,440 1,418,715 
Change in fair value of common stock warrant liabilities18,006,319 1,834,862 
(Loss) gain on investment in affiliated entity(2,103,688)1,471,504 
Net unrealized gain on available-for-sale equity securities173,298 899,523 
Other expense, net(2,000,110)(703,665)
Net loss$(25,695,256)$(43,214,109)
(a) Includes DMAb, DPROT and other research and development programs, net of contributions received from grant agreements and recorded as contra-research and development expense.